Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05598333 · ClinicalTrials.gov registry record · Phase 2
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
A Phase 2 study of Congestive Heart Failure, sponsored by AskBio.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT05598333 is a Phase 2 study of Congestive Heart Failure that is active but no longer recruiting, run by AskBio. The registered enrollment target is 150 participants, below the 327-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT05598333, a Phase 2 study of Congestive Heart Failure, is active but no longer recruiting, sponsored by AskBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF. Subjects will be randomized into one of three treatment groups in a 1:1:1
Conditions Studied
Interventions
- DRUG AB-1002
Study Locations (20)
California
- University of California Irvine Medical Center - Irvine
- University of California San Diego - La Jolla
- University of California San Francisco - San Francisco
Florida
- Baycare Medical Group - Clearwater
- University of Miami - Coral Gables
- University of Florida - Gainesville
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
- Mayo Clinic - Minnesota - Rochester
Missouri
- Aurora Saint Luke's Health System - Kansas City
- St. Louis University - St Louis
Alabama
- Cardiology P.C. Birmingham - Birmingham
Arizona
- University of Arizona Sarvor Heart Center - Tucson
Georgia
- Augusta University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05598333
The ClinicalTrials.gov registry entry for NCT05598333 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (54% lower). The listed sponsor is AskBio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which AB-1002 is the first listed.
NCT05598333 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05598333 about?
NCT05598333 is a clinical study titled "Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure". This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic cardiomyopathy and NYH...
What is the current status of trial NCT05598333?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2023-10-20. Estimated completion is 2030-12-31.
What conditions does trial NCT05598333 study?
This clinical trial studies the following conditions: Congestive Heart Failure.
What interventions are being tested in trial NCT05598333?
The interventions under investigation include: AB-1002 (DRUG).
Who is sponsoring clinical trial NCT05598333?
This trial is sponsored by AskBio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05598333 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congestive Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
At-Home Automated External Defibrillator (AED) Training Study
COMPLETED · Phase 2
-
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes
COMPLETED · Phase 2
-
Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF
COMPLETED · Phase 2
-
Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.
COMPLETED · Phase 2
-
Palliative Care for People With HF
RECRUITING
-
Circulating Markers for Ischemic Heart Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.